Sweden
Every company in the roster headquartered in Sweden.
Every company in the roster headquartered in Sweden.
10 of 10 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
AlzeCure PharmaALZCUR · Spotlight Stock Market | 1 asset: 1 Ph 1 | ACD856Phase 1 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Alzinova ABALZ · Nasdaq First North | 1 asset: 1 Ph 1 | ALZ-101Phase 1 · Alzheimer's DiseasePartial signal | None on record | — | — | — | — |
Pila PharmaPILA · Nasdaq First North | 1 asset: 1 Ph 2 | XEN-D0501Phase 2 · Type 2 DiabetesPartial signal | None on record | — | $1.7MDec 2025 | Ended Apr 2026 | — |
Xbrane Biopharma ABXBRANE · Nasdaq Stockholm | 1 asset: 1 Ph 3 | Ranibizumab (Ximluci)Phase 3 · Age-Related Macular Degeneration | None on record | — | — | — | — |
Alligator BiosciencePrivate | 1 asset: 1 Ph 2 | ALG.APV-527Phase 1/2 · Solid Tumors | None on record | — | — | — | — |
AnaCardio ABPrivate | 1 asset: 1 Ph 2 | AC01Phase 2 · Heart FailureWeak signal | 30 Jul 2028AC01 · Phase 2 | — | — | — | — |
Calliditas TherapeuticsPrivate | 1 asset: 1 approved | Approved assets only | Mar 2027Budesonide (targeted-release) · Approved | — | $75MJun 2024 | ~16.9 qtrs | $50M |
Empros PharmaPrivate | 1 asset: 1 Ph 2 | Orlistat/acarbose (EMP16)Phase 2 · ObesityReliable signal | None on record | — | — | — | — |
Linde HealthcarePrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
One-carbon Therapeutics ABPrivate | 1 asset: 1 Ph 2 | TH9619Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026TH9619 · Phase 1/2 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.